Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT03218241 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2023-08-04
Summary
This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose study of PRT064445 or its matching placebo, in healthy subjects.
Conditions
- Healthy
Interventions
- BIOLOGICAL
-
PRT064445
Intravenous
- DRUG
-
Intravenous to mimic PRT064445
Sponsors & Collaborators
-
Portola Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- DOUBLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2012-09-30
- Completion
- 2012-10-31
Countries
- United States
Study Locations
More Related Trials
-
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT03310021 ·Status: COMPLETED ·Phase: PHASE2
-
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT00375609 ·Status: COMPLETED ·Phase: PHASE2
-
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
NCT03330457 ·Status: TERMINATED ·Phase: PHASE2
-
Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant
NCT06372483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
NCT01159210 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
NCT00005684 ·Status: COMPLETED
-
A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal
NCT01759394 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Test the Accuracy of a Prototype Handheld PT/INR Device
NCT01349712 ·Status: UNKNOWN
-
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
NCT00443053 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects
NCT02949206 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage
NCT06974396 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
NCT03064035 ·Status: COMPLETED ·Phase: PHASE4
-
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT02220725 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
NCT00742859 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
NCT03311984 ·Status: UNKNOWN
-
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
NCT03363477 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
NCT02329327 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
NCT05152420 ·Status: COMPLETED ·Phase: PHASE1
-
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
NCT06662253 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)
NCT00182364 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
NCT03140631 ·Status: COMPLETED ·Phase: PHASE4
-
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
NCT05033314 ·Status: TERMINATED ·Phase: PHASE3
-
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
NCT00839163 ·Status: COMPLETED ·Phase: PHASE2
-
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department
NCT06692504 ·Status: RECRUITING
-
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
NCT04543383 ·Status: COMPLETED ·Phase: PHASE1